Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ Kallikrein 8 Monoclonal Antibody (OTI1D2)
Mouse Monoclonal Antibody
Supplier: Invitrogen™ MA526252
Description
Kallikrein 8 Monoclonal Antibody for Western Blot, ICC/IF, IHC (P)
Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in tandem in a gene cluster on chromosome 19. The encoded protein may be involved in proteolytic cascade in the skin and may serve as a biomarker for ovarian cancer. Alternate splicing of this gene results in multiple transcript variants encoding different isoforms.
Specifications
Kallikrein 8 | |
Monoclonal | |
1 mg/mL | |
PBS with 1% BSA, 50% glycerol and 0.02% sodium azide; pH 7.3 | |
O60259 | |
KLK8 | |
Full length human recombinant protein of KLK8 produced in HEK293T cell. | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG2a |
Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry | |
OTI1D2 | |
Unconjugated | |
KLK8 | |
brain serine protease 1; BSP1; EGK_10950; H NRPN; hK8; HNP; kallikrein 8; kallikrein 8 (neuropsin/ovasin); kallikrein related peptidase 8; kallikrein related-peptidase 8; Kallikrein8; kallikrein-8; kallikrein-related peptidase 8; Klk8; mK8; neuropsin; NP; Nrpn; Ovasin; PRO322; protease, serine, 19 (neuropsin); Prss19; Serine protease 19; serine protease TADG-14; TADG14; Tumor-associated differentially expressed gene 14 protein; UNQ283; UNQ283/PRO322 | |
Mouse | |
Affinity chromatography | |
RUO | |
11202 | |
-20°C, Avoid Freeze/Thaw Cycles | |
Liquid |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction